Incidence and predictors of heart failure following percutaneous coronary intervention in ST-segment elevation myocardial infarction: The HORIZONS-AMI trial

Nationwide trends in development of heart failure and mortality after first-time myocardial infarction 1997–2010: A Danish cohort study

“…Use of loop diuretics as a proxy for HF has previously been shown to accurately predict mortality while uncorrelated to estimated glomerular filtration rates among patients with heart failure, suggesting that loop diuretic doses in general reflect cardiac rather than renal dysfunction [14,17]. Previous studies have shown that HF due to MI most commonly develops within the first few months after MI [18][19][20][21], and therefore use of loop diuretics day 90 was chosen to define HF severity. The study period lasted from the 1st of January 1997 to the 31st of December 2010.…”

“…This study was conducted before the widespread use of PCI performed on days 0-1 and the reduction in HF incidence may therefore largely be explained by the benefits of improved medical therapy. A randomized, controlled trial of STEMI patients [21] who underwent PCI on days 0-1 after MI showed a very low number of patients developing HF (4.6% after 30 days and 5.1% after two years) and similarly a register-based study [30] showed a reduction in HF development coincident with a doubling in the proportion of patients who underwent PCI. These studies support the argument that both progress in medical therapy as well as in the availability and performance of revascularization procedures contribute to decreased risk of HF development.…”

Bivalirudin vs Heparin in Patients Who Undergo Transcatheter Aortic Valve Implantation

“…Nevertheless, compared with heparin, bivalirudin has been demonstrated to reduce access site and nonaccess site bleeding complications in patients who undergo percutaneous coronary intervention (PCI) compared with heparin with glycoprotein IIb/IIIa inhibitors. 7,8 Moreover, bivalirudin has been shown to reduce major or lifethreatening bleeding when used during balloon valvuloplasty of the aortic valve. 9 However, data regarding the performance of bivalirudin compared with weight-adjusted UFH peri-TAVI procedure are lacking.…”

Deciphering stem cell therapy for the interventional cardiologist

“…Unlike those patients who are in desperate need of some intervention for refractory lifestyle-limiting symptoms and high morbidity and mortality, the postmyocardial infarction patient may be entirely asymptomatic thus the difference in the targeted strategy. In this case, the goal of therapy is to somehow influence the adverse remodeling that occurs in a small percentage of patients post-STEMI despite successful intervention [10]. These patients can deteriorate much later in time and spiral quickly despite the best medical, surgical and interventional efforts to reverse it.…”